Alzheimer's disease: progress in prediction.
作者信息
Petersen Ronald C
机构信息
Alzheimer's Disease Research Center, Mayo Clinic College of Medicine, Rochester, MN, USA.
出版信息
Lancet Neurol. 2010 Jan;9(1):4-5. doi: 10.1016/S1474-4422(09)70330-8.
Abstract
摘要
相似文献
1
Alzheimer's disease: progress in prediction.
Lancet Neurol. 2010 Jan;9(1):4-5. doi: 10.1016/S1474-4422(09)70330-8.
2
The effect of APOE genotype on clinical phenotype in Alzheimer disease.
Neurology. 2007 Feb 20;68(8):624; author reply 624. doi: 10.1212/01.wnl.0000258354.96336.97.
3
The effects of stress and APOE genotype on cognition in older adults.
Am J Psychiatry. 2008 Nov;165(11):1376-8. doi: 10.1176/appi.ajp.2008.08081249.
4
Research criteria for the diagnosis of Alzheimer's disease: genetic risk factors, blood biomarkers and olfactory dysfunction.
Int Psychogeriatr. 2008 Aug;20(4):853-5. doi: 10.1017/S1041610208006807. Epub 2008 Apr 17.
5
Nature throws curveballs: APOE and nonlinear decline in Alzheimer disease.
Neurology. 2005 Dec 27;65(12):1855-6. doi: 10.1212/01.wnl.0000195338.67756.4b.
6
fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease.
Neurology. 2005 Nov 8;65(9):1514-5; author reply 1514-5. doi: 10.1212/wnl.65.9.1514-a.
7
Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans.
Alzheimers Dement. 2010 May;6(3):265-73. doi: 10.1016/j.jalz.2010.03.013.
8
[Signaling molecules in the brain and epigenetic factors in neurodegenerative and mental disorders].
Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(10):102-110. doi: 10.17116/jnevro2015115101102-110.
9
Relationship between cortisol levels and memory performance may be modulated by the presence or absence of cognitive impairment: evidence from healthy elderly, mild cognitive impairment and Alzheimer's disease subjects.
J Alzheimers Dis. 2010;19(3):839-48. doi: 10.3233/JAD-2010-1282.
10
APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease.
Neurology. 2008 May 6;70(19 Pt 2):1842-9. doi: 10.1212/01.wnl.0000304038.37421.cc. Epub 2008 Apr 9.
引用本文的文献
1
A glycan biomarker predicts cognitive decline in amyloid- and tau-negative patients.
Brain Commun. 2024 Oct 18;6(6):fcae371. doi: 10.1093/braincomms/fcae371. eCollection 2024.
2
FGFR3 drives Aβ-induced tau uptake.
Exp Mol Med. 2024 Jul;56(7):1631-1642. doi: 10.1038/s12276-024-01274-3. Epub 2024 Jul 1.
3
Evaluation of serum neurofilament light chain and glial fibrillary acidic protein in the diagnosis of Alzheimer's disease.
Front Neurol. 2024 Jan 30;15:1320653. doi: 10.3389/fneur.2024.1320653. eCollection 2024.
4
Validation of the Antioxidant and Enzyme Inhibitory Potential of Selected Triterpenes Using In Vitro and In Silico Studies, and the Evaluation of Their ADMET Properties.
Molecules. 2021 Oct 20;26(21):6331. doi: 10.3390/molecules26216331.
5
Identifying Individuals With Mild Cognitive Impairment Using Working Memory-Induced Intra-Subject Variability of Resting-State EEGs.
Front Comput Neurosci. 2021 Aug 4;15:700467. doi: 10.3389/fncom.2021.700467. eCollection 2021.
6
Association between handgrip strength and cognition in a Chinese population with Alzheimer's disease and mild cognitive impairment.
BMC Geriatr. 2021 Aug 11;21(1):459. doi: 10.1186/s12877-021-02383-8.
7
Phytochemical Composition, Antioxidant Activity, and Enzyme Inhibitory Activities (α-Glucosidase, Xanthine Oxidase, and Acetylcholinesterase) of .
Molecules. 2021 Jul 24;26(15):4472. doi: 10.3390/molecules26154472.
8
Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer's disease.
Alzheimers Res Ther. 2021 Apr 20;13(1):84. doi: 10.1186/s13195-021-00817-4.
9
Automated Multiclass Classification of Spontaneous EEG Activity in Alzheimer's Disease and Mild Cognitive Impairment.
Entropy (Basel). 2018 Jan 9;20(1):35. doi: 10.3390/e20010035.
10
Differential Expression and miRNA-Gene Interactions in Early and Late Mild Cognitive Impairment.
Biology (Basel). 2020 Aug 28;9(9):251. doi: 10.3390/biology9090251.
本文引用的文献
1
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.
Neurology. 2010 Jan 19;74(3):201-9. doi: 10.1212/WNL.0b013e3181cb3e25. Epub 2009 Dec 30.
2
Mild cognitive impairment: ten years later.
Arch Neurol. 2009 Dec;66(12):1447-55. doi: 10.1001/archneurol.2009.266.
3
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease.
Nat Genet. 2009 Oct;41(10):1094-9. doi: 10.1038/ng.439. Epub 2009 Sep 6.
4
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.
Nat Genet. 2009 Oct;41(10):1088-93. doi: 10.1038/ng.440. Epub 2009 Sep 6.
5
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
JAMA. 2009 Jul 22;302(4):385-93. doi: 10.1001/jama.2009.1064.
6
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.
Lancet Neurol. 2009 Jul;8(7):619-27. doi: 10.1016/S1474-4422(09)70139-5. Epub 2009 Jun 10.
7
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.
Brain. 2009 May;132(Pt 5):1355-65. doi: 10.1093/brain/awp062. Epub 2009 Mar 31.
8
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.
Ann Neurol. 2009 Apr;65(4):403-13. doi: 10.1002/ana.21610.
9
Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects.
Brain. 2009 May;132(Pt 5):1310-23. doi: 10.1093/brain/awn320. Epub 2008 Nov 28.
Zotero 插件